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However, some studies showed that adjuvant HT may be 
associated with worse radio-induced toxicity although this 
topic remains controversial. Therefore, the purpose of this 
study was to evaluate the impact of the HT (in terms of drug 
type and duration) on acute and late toxicity in patients 
undergoing RT for PCa. 
Materials and Methods: We collected data from 8 clinical 
trials on RT of PCa. Acute toxicity was assessed according to 
the RTOG scale and late toxicity according to RTOG-EORTC 
scale. The results in terms of acute toxicity were compared 
with the chi-square test. Late toxicity actuarial cumulative 
incidence was calculated by Kaplan-Meier method and the 
comparison between survival curves was performed using log-
rank test (univariate analysis) and Cox's Proportional Hazard 
Method (multivariate analysis using as covariates: RT dose, 
fractionation and prophylactic lymph node irradiation).  
Results: Overall 346 patients were included in this analysis 
(median age: 72 years, range: 50-82; median RT dose: 70 Gy, 
range: 65-80; LH-RH analogue: 51.4%, high-dose antiandrogen 
[bicalutamide 150 mg/die]: 48.6%; HT for 6 months: 50.3%, 
HT for 24 months: 49.7%). The results of the statistical 




The higher incidence of GI late toxicity in patients receiving 
adjuvant hormone therapy with LH-RH analogue was 
confirmed by multivariate analysis (p: 0.038). 
Conclusions: In an evaluation of radiation-induced toxicity in 
patients undergoing RT plus adjuvant HT, a higher incidence 
of late GI toxicity was recorded in patients treated with LH-
RH analogues compared with patients treated with 
antiandrogen. This result warrants further studies to optimize 
adjuvant therapies in patients with PCa.  
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Purpose/Objective: To assess the toxicity of combined 
therapy between external beam radiation therapy (EBRT) 
plus high dose rate brachytherapy (HDRB) as a boost in 
patients with intermediate or high risk prostate cancer. 
Materials and Methods: From 2010 to August 2014, a total of 
221 patients diagnosed as intermediate or high-risk prostate 
cancer were treated with EBRT plus HDRB. Median age was 72 
years (range 52-85). Most patients (68%) were classified as 
high-risk (stage T2c-T3b or PSA >20ng/dl or GS>7), and 70 
patients (32%) were considered intermediate risk. The stage 
of tumor was determined in every case by magnetic 
resonance imaging (MRI). Every patient received first HDRB as 
boost and 4 gold fiducials were implanted. Finally, all 
patients received EBRT by intensity modulated radiotherapy 
technique with imaging guided by CBCT. The patients 
received HDRB as a single 15 Gy implant, followed by EBRT to 
46 Gy in 23 fractions. Thirty seven percent of the high-risk 
patients presented seminal vesicles invasion receiving a 
single 9.5 Gy implant, followed by ERBT to 60 Gy in 30 
fractions. A total of 117 patients (52%) received a dose of 46 
Gy to the true pelvis. In all brachytherapy plans, the 
constraints indicated in the GEC/ESTRO recommendations 
have been respected (Rectum D2cc £75Gy EQD2; Urethra 
D10£ 120Gy EQD2). Most patients (120; 54%) were prescribed 
complete androgen deprivation therapy (ADT), 66 (29%) 
received incomplete ADT and 28 (13%) did not receive ADT. 
GI and GU toxicity was evaluated utilizing the RTOG criteria. 
Median follow-up was 26 months. 
Results: No treatment failure has been observed to the last 
follow-up. The incidences of any acute ≥ Grade 2 GI or GU 
toxicities were 0% and 9% respectively. Dysuria and urgency 
was prevalent symptoms in acute GU toxicity. Late 
genitourinary toxicity included 2 patients (0.9%) with urine 
obstruction requiring intermittent/permanent catheter. One 
case of grade 2 gastrointestinal late toxicity presented 
actinic rectitis event. 
Conclusions: The use of a single 15Gy fraction HDRB as pre-
treatment EBRT boost provides early-term and good 
outcomes in treatment-related toxicity. These data can help 
physicians to assess this scheme of radiotherapy as an 
acceptable option in the prostate carcinoma treatment.  
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Purpose/Objective: The use of hypofractionation allows to 
reduce the duration of radiotherapy (RT) and is theorically 
associated with an improved probability of cure in patients 
with prostate cancer (CAP). However, hypofractionated RT 
could be associated to an higher incidence of late side 
effects. Several studies are in progress to valuate efficacy of 
this irradiation modality but there are no definitive 
indications about tolerability and efficacy of this 
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fractionation. The purpose of this study was to define the 
maximum tolerated dose of an hypofractionated RT 
treatment based on IGRT-IMRT-SIB technique with final boost 
by IGRT-stereo-VMAT technique. 
Materials and Methods: Intermediate-high risk CAP patients 
(NCCN categories) were enrolled in consecutive cohorts 
treated with increasing RT doses. In the first cohort patients 
received a dose of 45 Gy (1,8 Gy/fraction) on pelvic lymph 
nodes and a concurrent boost with total dose of 65 Gy (2,6 
Gy/fraction) on prostate +/- seminal vesicles, using IMRT-SIB 
technique after implantation of intraprostatic fiducials. In 
the second cohort patients also received a final boost of 5 Gy 
in single fraction with stereotactic-VMAT technique. An 
adjuvant hormone therapy of 6 (intermediate risk) and 24 
months (high risk) was prescribed. Proctoscopy was 
performed to evaluate rectal toxicity using the Wachter-
Score one year after the end of RT. The study design allowed 
dose escalation in case of < 3/25 (12%) evaluable patients 
with Wachter-score > 3. 
Results: Sixty patients were recruited in the first cohort and 
139 patients in the second cohort (total: 199 patients; 
median age: 73 years (range: 50-82); median PSA: 8,7 ng/ml 
(range: 0,15-83,0); cT3-4: 41,8%; Gleason score > 7: 29,6%). 
The 3-year biochemical recurrence-free survival was 91,6%. 
The analysis results are reported in the table. 
Conclusions: In a dose-escalation study, the use of IGRT-
VMAT-SIB technique with hypofractionated total dose of 65 
Gy resulted feasible in terms of acute and late toxicity, with 
positive preliminar results in terms of biochemical control. 
Stereotactic boost (with total dose of 70 Gy) did not increase 
toxicity rates.  
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Purpose/Objective: Some evidence suggests that there is a 
significant correlation between acute and late rectal toxicity 
after radiotherapy. The purpose of this analysis is to test this 
hypothesis in a large sample of patients (597), treated with 
adjuvant radiotherapy (RT) +/- hormonal therapy (HT). 
Materials and Methods: The results, in terms of acute and 
late toxicity, were analyzed and compared in a population of 
patients enrolled in 8 different clinical studies. Acute toxicity 
was evaluated according to the RTOG scale and late toxicity 
was evaluated according to the RTOG-EORTC scale. The 
cumulative actuarial late toxicity was calculated using the 
Kaplan-Meier method and comparison of survival curves was 
performed by logrank test (univariate analysis) and Cox's 
proportional hazard method (multivariate analysis, using as a 
covariate: radiotherapy dose, fractionation, prophylactic 
lymph node irradiation, adjuvant hormonal therapy ). 
Results: 597 patients, treated with radiotherapy were 
evaluated; 91.5% of patients received adjuvant hormonal 
therapy (LH-RH analogue: 49,9%; antiandrogen agent 
[bicalutamide, 150 mg per day]: 41.6%). The results of 
statistical analysis are shown in the table. There is a 
statistical correlation between acute and grade 1 and 2 late 
rectal toxicity, both at univariate and multivariate analysis. 
 
 
Conclusions: The results of this analysis confirm the close 
correlation between acute and late radio-induced rectal 
toxicity. These results suggest that excessive early damage to 
the 'acute-respoding' component of the rectal wall plays an 
important role in the genesis of late toxicity. Radiation 
proctitis is thus confirmed, at least in part, as a 
'consequential' effect. This justifies the use of acute toxicity 
as surrogate end-point of late complications in dose-finding 
studies on radiation therapy of prostate cancer.  
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Purpose/Objective: Traditionally, seminal vesicle invasion 
(T3b) was diagnosed by digital rectal examination or 
transrectal ultrasound. In the recent years diagnostic MRI has 
become available, a technique that is much more sensitive 
and can detect even minimal invasion. It is, however, unclear 
whether a MRI based T3b (MR-T3b) has the same poor 
prognosis as a clinically staged T3b (cT3b). We therefore 
compared the clinical outcome of MR T3b with that of cT3b 
prostate carcinoma (PC). 
Materials and Methods: Patients (n=90, cohort A) were 
treated with (78 Gy) image-guided IMRT for localized PC 
between 2008 – 2010 and had diagnostic signs of SV invasion 
on the planning MRI; 60 % was prescribed 3y of adjuvant 
hormonal treatment (AHT) because of clinical high-risk 
features. Pre-RT screening for positive LN was performed. 
Patient and tumor characteristics were compared with a 
previous cohort B (n=87) treated in 1997 – 2002 (68 Gy or 78 
Gy) with 3D conformal RT (32 % received 3y AHT). Freedom 
from failure (FFF) was scored according the Phoenix 
definition. Multivariate Cox regression (MV) was applied to 
determine significant predictive factors for freedom from 
failure (FFF). 
